What is Supernus Pharmaceuticals Inc (SUPN) stock price today?

Supernus Pharmaceuticals Inc (SUPN) currently trades at $48.55 per share. The stock has a market capitalization of $2.80B and a P/E ratio of —x.

Is SUPN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Supernus Pharmaceuticals Inc has a Smart Value Score of 52/100 (Grade C), resulting in a "Hold" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Supernus Pharmaceuticals Inc's revenue and earnings?

Supernus Pharmaceuticals Inc has trailing twelve-month (TTM) revenue of $718.95M with profit margins of -5.36%. Earnings per share (EPS) is $-0.68.

SUPN

Supernus Pharmaceuticals Inc

NASDAQ: SUPN · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$48.55

-0.29% today

Updated 2026-04-29

Market cap

$2.80B

P/E ratio

—

P/S ratio

3.89x

EPS (TTM)

$-0.68

Dividend yield

—

52W range

$29 – $60

Volume

0.7M

Market cap

$2.80B

P/E ratio

—

P/S ratio

3.89x

EPS (TTM)

$-0.68

Dividend yield

—

52W range

$29 – $60

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: C

Hold

Investment rating

6.0

Growth

5.0

Quality

C+

3.5

Profitability

5.3

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$62.67

+29.08%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Free cash flow $19.43M — positive

+ Revenue growth 21.50% QoQ

Risks

- Thin margins at -5.36%

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$667.24M	$607.52M	$661.82M	$718.95M	$718.95M
Net income	$60.71M	$1.32M	$73.86M	$-38.55M	$-4.11M
EPS	—	—	—	—	$-0.68
Free cash flow	$116.41M	$110.53M	$171.23M	$45.99M	$19.43M
Profit margin	9.10%	0.22%	11.16%	-5.36%	-5.36%

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
SUPN	$2.80B	52	6.0	3.5	5.3	5.0	—	Buy
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Supernus Pharmaceuticals Inc trades at $48.55. Our Smart Value Score of 52/100 indicates the stock is fair. TTM revenue stands at $718.95M. with profit margins at -5.36%.

Frequently asked questions

What is Supernus Pharmaceuticals Inc's stock price?

Supernus Pharmaceuticals Inc (SUPN) trades at $48.55.

Is Supernus Pharmaceuticals Inc overvalued?

Smart Value Score 52/100 (Grade C, Hold).

What is the price target of Supernus Pharmaceuticals Inc (SUPN)?

The analyst target price is $62.67, representing +29.1% upside from the current price of $48.55.

What is Supernus Pharmaceuticals Inc's revenue?

TTM revenue is $718.95M.

Company info

SectorHEALTHCARE

IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio3.89x

ROE-3.68%

Beta0.73

50D MA$51.27

200D MA$47.47

Shares out0.06B

Float0.05B

Short ratio—

Avg volume0.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

SUPN vs LLY →SUPN vs JNJ →SUPN vs ABBV →Stock screener →